Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
7 items
A randomized clinical trial found low-dose IL-2 improved disease activity and immune balance in Sjögren’s syndrome.
View — Low-Dose IL-2 Therapy Shows Promise in Sjögren’s Syndrome Clinical Trial »The FDA has granted Breakthrough Therapy designation to ianalumab, a potential targeted treatment for Sjögren’s disease.
View — FDA Grants Breakthrough Therapy Status to Ianalumab for Sjögren’s Disease »Multiple new drugs targeting immune pathways are showing encouraging results in Sjögren’s clinical trials.
View — Emerging Sjögren’s Treatments Show Promise in Clinical Trials »Novartis announces that ianalumab, a dual-mechanism B-cell depleting antibody, achieved statistically significant reductions in Sjögren's d...
View — Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials »A 2025 meta-analysis pooled data from multiple clinical trials to offer the most comprehensive picture yet of how well rituximab works for p...
View — Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome »Researchers at the University of Wisconsin are testing a novel cell therapy for dry mouth caused by Sjögren's disease. The FDA has granted...
View — Cell Therapy for Sjögren's Disease Dry Mouth Earns FDA Fast Track Designation »